Searched for: subject%3A%22blood%255C%2Bclotting%22
(1 - 20 of 64)

Pages

document
Khedoe, P.P.S.J. (author), Wong, M.C. (author), Wagenaar, G.T.M. (author), Plomp, J.J. (author), van Eck, M. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), Hiemstra, P.S. (author), Berbée, J.F.P. (author)
Background: Chronic obstructive pulmonary disease (COPD) is characterized by pulmonary inflammation, airways obstruction and emphysema, and is a risk factor for cardiovascular disease (CVD). However, the contribution of these individual COPD components to this increased risk is unknown. Therefore, the aim of this study was to determine the...
article 2013
document
Haas, F.J.L.M. (author), Kluft, C. (author), Biesma, D.H. (author), Schutgens, R.E.G. (author)
The objective of the present study was to evaluate the influence of thrombophilia risk factors on variables of a chromogenic thrombin generation assay (ETP) in a setting with acute deep venous thrombosis (DVT) and non-DVT patients. In 152 outpatients suspected for DVT, the results of thrombophilia investigations were known. In all patients,...
article 2011
document
TNO Kwaliteit van Leven (author), Bijland, S. (author), Pieterman, E.J. (author), Maas, A.C.E. (author), van der Hoorn, J.W.A. (author), van Erk, M.J. (author), van Klinken, J.B. (author), Havekes, L.M. (author), van Dijk, K.W. (author), Princen, H.M.G. (author), Rensen, P.C.N. (author)
The peroxisome proliferator-activated receptor alpha (PPARalpha) activator fenofibrate efficiently decreases plasma triglycerides (TG), which is generally attributed to enhanced very low density lipoprotein (VLDL)-TG clearance and decreased VLDL-TG production. However, because data on the effect of fenofibrate on VLDL production are...
article 2010
document
Kienhuis, A.S. (author), van de Poll, M.C.G. (author), de Jong, C.H.C. (author), Gottschalk, R. (author), van Herwijnen, M. (author), Boorsma, A. (author), Kleinjans, J.C.S. (author), Stierum, R.H. (author), van Delft, J.H.M. (author), TNO Kwaliteit van Leven (author)
A compound for which marked species differences have been reported in laboratory animals and humans is coumarin. In rats, metabolites of coumarin are highly toxic, whereas in humans, the compound is mainly metabolized to non-toxic metabolites. In the present study, a toxicogenomics-based parallelogram approach was used to compare effects of...
article 2009
document
Parker, A.L. (author), Waddington, S.N. (author), Buckley, S.M.K. (author), Custers, J. (author), Havenga, M.J.E. (author), van Rooijen, N. (author), Goudsmit, J. (author), McVey, J.H. (author), Nicklin, S.A. (author), Baker, A.H. (author), TNO Kwaliteit van Leven (author)
The deployment of adenovirus serotype 5 (Ad5)-based vectors is hampered by preexisting immunity. When such vectors are delivered intravenously, hepatocyte transduction is mediated by the hexon-coagulation factor X (FX) interaction. Here, we demonstrate that human sera efficiently block FX-mediated cellular binding and transduction of Ad5-based...
article 2009
document
Geert Heidema, A. (author), Thissen, U. (author), Boer, J.M.A. (author), Bouwman, F.G. (author), Feskens, E.J.M. (author), Mariman, E.C.M. (author), TNO Kwaliteit van Leven (author)
In this study, we applied the multivariate statistical tool Partial Least Squares (PLS) to analyze the relative importance of 83 plasma proteins in relation to coronary heart disease (CHD) mortality and the intermediate end points body mass index, HDL-cholesterol and total cholesterol. From a Dutch monitoring project for cardiovascular disease...
article 2009
document
Kluft, C. (author), Meijer, P. (author), LaGuardia, K.D. (author), Fisher, A.C. (author), TNO Kwaliteit van Leven (author)
Purpose: The aim of this study was to compare effects of the transdermal contraceptive patch, a desogestrel/ethinyl estradiol (EE)-containing, monophasic combination oral contraceptive (COC) and a levonorgestrel/EE-containing, triphasic COC on hemostasis variables. Study Design: This was a randomized, open-label study of 104 young women who...
article 2008
document
Rijken, D.C. (author), Hoegee-de Nobel, E. (author), Jie, A.F.H. (author), Atsma, D.E. (author), Schalij, M.J. (author), Nieuwenhuizen, W. (author), TNO Kwaliteit van Leven (author)
Background: The development of global tests for the fibrinolytic capacity in blood is hampered by the low base-line fibrinolytic activity in blood, by the involvement of both plasmatic components and blood cells in the fibrinolytic system and by the loss of fibrinolytic activity as a result of the action of plasminogen activator inhibitor-1 (PAI...
article 2008
document
Schreijer, A.J.M. (author), Cannegieter, S.C. (author), Caramella, M. (author), Meijers, J.C.M. (author), Krediet, R.T. (author), Simons, M. (author), Rosendaal, F.R. (author), TNO Defensie en Veiligheid (author)
The mechanism of air travel-related venous thrombosis is unclear. Although immobility plays a pivotal role, other factors such as fluid loss may contribute. We investigated whether fluid loss occurred more in individuals with coagulation activation after air travel than in subjects without. As a secondary aim, we investigated whether fluid loss...
article 2008
document
Hemelaar, M. (author), van der Mooren, M.J. (author), Rad, M. (author), Kluft, C. (author), Kenemans, P. (author), TNO Kwaliteit van Leven (author)
Objective: To review the effects of non-oral administration of postmenopausal hormone therapy (HT) on risk markers for atherosclerotic and venous thromboembolic disease.Non-oral postmenopausal HT appears not to increase venous thromboembolic risk, whereas the effect on coronary heart disease risk is less clear. Design: Systematic review of...
article 2008
document
Norris, L.A. (author), Brosnan, J. (author), Bonnar, J. (author), Conard, J. (author), Kluft, C. (author), Hellgren, M. (author), TNO Kwaliteit van Leven (author)
Epidemiological studies have shown that hormone therapy (HT) increases the risk of venous thromboembolism in post menopausal women. The mechanism of this increased risk is unknown; however, activation of the haemostatic system is known to contribute to the pathogenesis of venous thromboembolism. In post-menopausal women the estrogen /progestogen...
article 2008
document
Emeis, J.J. (author), Jirouskova, M. (author), Muchitsch, E.-M. (author), Shet, A.S. (author), Smyth, S.S. (author), Johnson, G.J. (author), TNO Preventie en Gezondheid (author)
Murine blood coagulation factors and function are quite similar to those of humans. Because of this similarity and the adaptability of mice to genetic manipulation, murine coagulation factors and inhibitors have been extensively studied. These studies have provided significant insights into human hemostasis. They have also provided useful...
article 2007
document
Rad, M. (author), Kluft, C. (author), Ménard, J. (author), Burggraaf, J. (author), de Kam, M.L. (author), Meijer, P. (author), Sivin, I. (author), Sitruk-Ware, R.L. (author), TNO Kwaliteit van Leven (author)
Objective: This study aimed to compare the effects on hemostasis variables of a contraceptive vaginal ring with those of an oral contraceptive. Study design: Twenty-three and 22 healthy premenopausal women were randomized to the contraceptive vaginal ring (150 μg Nestorone and 15 μg ethinyl estradiol) or Stediril 30 during 3 cycles. Analysis of...
article 2006
document
Bertina, R.M. (author), van Tilburg, N.H. (author), Haverkate, F. (author), Bouma, B.N. (author), von dem Borne, P.A.K. (author), Meijers, J.C.M. (author), Campbell, W. (author), Eaton, D. (author), Hendriks, D.F. (author), Willemse, J.L. (author), TNO Kwaliteit van Leven (author)
CAS: blood clotting factor 11, 9013-55-2; thrombin, 9002-04-4; tissue plasminogen activator, 105913-11-9; protein C, 60202-16-6; Carboxypeptidase U, 3.4.17.20; Protein C; Tissue Plasminogen Activator, 3.4.21.68
article 2006
document
TNO Kwaliteit van Leven (author), Guimarães, A.H.C. (author), Barrett-Bergshoeff, M.M. (author), Criscuoli, M. (author), Evangelista, S. (author), Rijken, D.C. (author)
In this study, the in-vitro fibrinolytic efficacy of Tenecteplase, Amediplase and scu-PA was investigated in different external lysis models by measuring the lysis of human plasma clots after the addition of the plasminogen activators (PAs) to the surrounding plasma. The effect of TAFI was examined for each PA by neutralising TAFIa with potato...
article 2006
document
Vogelvang, T.E. (author), Mijatovic, V. (author), Kenemans, P. (author), Emeis, J.J. (author), Heijst, J.A. (author), van der Mooren, M.J. (author), TNO Preventie en Gezondheid (author)
Objective: To investigate the short-term effects of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis. Study design: In a multicenter, 14-week, randomized, placebo-controlled, double-blind, dose-ranging study, healthy postmenopausal women received daily placebo (n = 22), HMR 3339 2.5 mg (n = 25),...
article 2005
document
Bovenschen, N. (author), van Dijk, K.W. (author), Havekes, L.M. (author), Mertens, K. (author), van Vlijmen, B.J.M. (author), Gaubius Instituut TNO (author)
Low-density lipoprotein receptor-related protein (LRP) contributes to factor VIII (FVIII) catabolism in vivo. Besides LRP, FVIII also interacts with very low-density lipoprotein receptor (VLDLR) in vitro. We investigated the physiological role of VLDLR in FVIII catabolism, using knockout mouse models for VLDLR and LRP, alone and in combination....
article 2004
document
Espirito Santo, S.M.S. (author), Pires, N.M.M. (author), Boesten, L.S.M. (author), Gerritsen, G. (author), Bovenschen, N. (author), van Dijk, K.W. (author), Jukema, J.W. (author), Princen, H.M.G. (author), Bensadoun, A. (author), Li, W.P. (author), Herz, J. (author), Havekes, L.M. (author), van Vlijmen, B.J.M. (author), Gaubius Instituut TNO (author)
The low-density lipoprotein (LDL) receptor-related protein (LRP) has a well-established role in the hepatic removal of atherogenic apolipoprotein E (APOE)-rich remnant lipoproteins from plasma. In addition, LRP recognizes multiple distinct pro- and antiatherogenic ligands in vitro. Here, we investigated the role of hepatic LRP in atherogenesis...
article 2004
document
Rijken, D.C. (author), Barrett-Bergshoeff, M.M. (author), Jie, A.F.H. (author), Criscuoli, M. (author), Sakharov, D.V. (author), Gaubius Instituut TNO (author)
Amediplase (K2tu-PA) is a hybrid plasminogen activator, consisting of the kringle 2 domain of alteplase and the protease domain of urokinase. The objective of this study was to determine the in vitro clot penetration of amediplase in relation to its fibrin binding and to compare the properties with those of alteplase. The clot lysis activity of...
article 2004
document
van Schoonbeek, K. (author), Feijge, M.A.H. (author), Paquay, M. (author), Rosing, J. (author), Saris, W. (author), Kluft, C. (author), Giesen, P.L.A. (author), Maat, M.P.M.de (author), Heemskerk, J.W.M. (author), TNO Preventie en Gezondheid (author)
Objective-The beneficial effect of dietary fish oil, rich in omega-3 polyunsaturated fatty acids (PUFAs), on cardiovascular disease is multifactorial and may partly rely on their anticoagulant action. We studied how fish oil intake influenced thrombin generation in plasma and which factors were involved herein. Methods and Results-Twenty-five...
article 2004
Searched for: subject%3A%22blood%255C%2Bclotting%22
(1 - 20 of 64)

Pages